The present invention provides a bone cement composition kit. The bone cement composition kit includes a bone matrix component and a hydrogel component, respectively stored in separate containers, wherein the bone matrix component includes a bone matrix, the hydrogel component includes an acrylic polymer and an acrylic monomer. A ratio of the bone matrix component to the hydrogel component is in a range from about 1:2 (mL/mL) to about 1:50 (mL/mL).

An adhesive for moist tissue is formulated including a silicone elastomer, a crosslinked polyacrylic acid polymer and a sodium polyacrylate based superabsorbent polymer. The adhesive adheres well to moist tissue, such as a mucosal skin surface. An ostomy skin barrier including a stoma seal made using the adhesive is also disclosed.

The present invention relates to a flowable bone graft material including an inorganic composition comprising calcium phosphate having a particle size of about 100 m to about 1,000 m, bioactive glass, and one or more biocompatible polymers comprising carboxymethyl cellulose and a fluid.

The present invention relates to a flowable bone graft material including an inorganic composition comprising calcium phosphate having a particle size of about 100 m to about 1,000 m, bioactive glass, and one or more biocompatible polymers comprising carboxymethyl cellulose and a fluid.

The present invention relates to a method that includes providing a formulation having an isocyanate-functional prepolymer and a curing component comprising an amino-functional aspartic ester of the general formula (I)

##STR00001##

applying the formulation to a cell tissue; and curing the formulation such that the loss of blood (haemostatic) or tissue fluids is staunched or leaks in cell tissues are sealed.

The present invention relates to a method that includes providing a formulation having an isocyanate-functional prepolymer and a curing component comprising an amino-functional aspartic ester of the general formula (I)

##STR00001##

applying the formulation to a cell tissue; and curing the formulation such that the loss of blood (haemostatic) or tissue fluids is staunched or leaks in cell tissues are sealed.

Certain configurations of adhesive materials are described which comprise a crosslinked derivatized atelocollagen. In some configurations, the crosslinked, derivatized atelocollagen is cured to provide a burst strength of at least 55 kPa or 60 kPa (or more) as tested by ASTM F2392-04. In some instances, the crosslinked derivatized atelocollagen comprises a methylated atelocollagen that is crosslinked using one or more functionalized crosslinking agents.

Techniques for deep tissue in vivo printing are described. Some implementations of the disclosure relate to a method that includes: obtaining a biopolymer mixture including prepolymer material and a crosslinking agent encapsulated in carrier particles; delivering the biopolymer mixture to a subcutaneous or deep tissue target location of a subject; and transmitting with a bioprinting device, via transcutaneous application, radiation to the subcutaneous or deep tissue target location, the radiation configured to cause the carrier particles to release at least some of the crosslinking agent, the released crosslinking agent configured to cause the prepolymer material to form into a gel or polymeric matrix.

A malleable sustained release formulation is created utilizing a local anesthetic wherein the composition is made sustained release by incorporating it into a bovine or porcine hemostatic agent. The composition is malleable enough to fit into a cavity such as a dental cavity and form the shape of the cavity. In addition to providing sustained release of the anesthetic, the composition also provides quicker reduction in bleeding.

A task of the invention is to provide an art that inhibits the hemorrhagic activity exhibited by sulfated glycosaminoglycans, as well as a material, a medical material, and a drug that use a sulfated glycosaminoglycan while being free of the hemorrhaging problems caused by sulfated glycosaminoglycans and that can exhibit an excellent therapeutic effect on biological tissues. The present invention relates to an inhibitor of the hemorrhagic activity originating from sulfated glycosaminoglycans, the inhibitor having a cationized chitosan as an active ingredient.